An “encounter for screening” on your medical records or patient portal does not mean you have colon cancer. It is a standard billing and coding phrase that indicates a routine preventive visit, the kind of appointment healthy people schedule precisely because they do not have symptoms or a known diagnosis. The term comes from the ICD-10 medical coding system, where codes starting with Z12.11 specifically denote “encounter for screening for malignant neoplasm of colon,” and it simply tells your insurance company that your doctor ordered a preventive test. If anything, seeing this phrase is a sign the system is treating you as someone at average risk who is doing the right thing by getting checked.
Why This Phrase Looks Scary on a Patient Portal
The anxiety is understandable. You open your patient portal expecting something reassuring, and instead you see the word “malignant neoplasm” next to your name. Medical coding language was never designed for patients to read. It was built for billing departments and insurance companies, and it uses clinical terminology that can sound alarming when you stumble across it without context. “Encounter for screening for malignant neoplasm of colon” is the system’s way of saying “this person came in for a routine colon cancer check.” The word “screening” is the key: it signals prevention, not diagnosis.
Research confirms that patients frequently experience negative emotions when viewing test results and medical records online. A study in the Journal of the American Medical Informatics Association found that over half of patients who received abnormal results experienced confusion, anxiety, or fear when viewing them through a portal, and nearly a quarter of patients with completely normal results still felt negative emotions just from seeing the clinical language.1Journal of the American Medical Informatics Association. Patient perceptions of receiving test results via online portals: a mixed-methods study Portal systems have gotten better at releasing results quickly, but they have not kept pace with making the language understandable to non-medical readers. The gap between what the code means and what it sounds like it means is real, and you are not unusual for being worried.
Screening Versus Diagnostic: A Distinction That Matters for Your Bill
In medical billing, there is a sharp line between a screening procedure and a diagnostic one, and understanding it can save you both anxiety and money. A screening procedure is one performed on a person who has no symptoms and no prior diagnosis. It is purely preventive. A diagnostic procedure is one performed because something has already raised a flag: you reported symptoms like blood in your stool, you had an abnormal stool test, or your doctor noticed something that needs further investigation.
This distinction has real financial consequences. Under the Affordable Care Act, most private insurance plans are required to cover recommended preventive screenings with no out-of-pocket cost to you. That includes colonoscopies for colorectal cancer screening at the recommended ages. However, if the procedure is reclassified as diagnostic, you could be responsible for copays, coinsurance, or deductible charges. Research has shown that the ACA’s removal of cost-sharing for preventive screening helped reduce disparities in colonoscopy use among insured older adults.2PubMed. Decomposing socioeconomic disparities in the use of colonoscopy among the insured elderly population before and after the Affordable Care Act But the coverage depends on the code. If your visit is coded as “encounter for screening,” that is the code that triggers the preventive coverage. If it is later recoded to a diagnostic encounter because something was found during the procedure, you may see different charges.
A common scenario that trips people up: you go in for a routine screening colonoscopy, everything is covered, and during the procedure the doctor finds and removes a small polyp. Some insurers have historically reclassified the procedure as diagnostic at that point, which could generate a surprise bill. Federal rules have been tightened to limit this practice for many plans, but it is still worth asking your insurance company upfront how polyp removal during a screening colonoscopy is handled on your specific plan.
When You Should Be Getting Screened
The U.S. Preventive Services Task Force, the body that sets widely followed screening guidelines, recommends colorectal cancer screening for all adults starting at age 45, continuing through age 75.3JAMA. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement For adults between 76 and 85, the recommendation becomes selective, meaning you and your doctor should weigh your overall health, your screening history, and your preferences. The evidence suggests the benefit of screening this older group is small on average, though it may still make sense for individuals who have never been screened or who are in good health.
The lowering of the starting age from 50 to 45 is relatively recent and reflects rising rates of colorectal cancer in younger adults. If you are in your mid-40s and your doctor has ordered a screening, that is consistent with current guidelines and not a sign that something is wrong.
People with a strong family history of colorectal cancer often need to start screening earlier and be screened more frequently. Australian national guidelines, for example, recommend that people with a moderate family risk begin stool-based screening at age 40 and colonoscopy at age 50, while those at high risk due to family history should begin stool-based screening at 35 and colonoscopy at 45.4PubMed. Revised Australian national guidelines for colorectal cancer screening: family history In the U.S., similar principles apply, with guidelines generally recommending earlier and more frequent screening when a first-degree relative has had colorectal cancer, especially if they were diagnosed young.
The Different Types of Screening Tests
Colonoscopy is the test most people picture when they think of colon cancer screening, but it is not the only option. Your doctor might order a stool-based test instead, which you complete at home. The main stool-based options are the fecal immunochemical test, commonly called FIT, and the multitarget stool DNA test (sold under brand names you have probably seen advertised on television). Both look for signs of cancer or precancerous growths in a stool sample, but they work differently and have different strengths.
A large trial comparing the multitarget stool DNA test to FIT found that the DNA test caught about 92% of actual colorectal cancers, while FIT caught about 74%.5PubMed. Multitarget Stool DNA Testing for Colorectal-Cancer Screening The DNA test was also better at finding precancerous growths, though it still only detected roughly 42% of advanced precancerous lesions. The tradeoff is specificity: the DNA test produces more false positives, meaning it is more likely to flag something that turns out not to be cancer, which leads to follow-up colonoscopies that may ultimately be unnecessary.
A newer version of the multitarget stool DNA test, evaluated in a more recent trial, showed similar results: about 94% sensitivity for colorectal cancer and 43% for advanced precancerous lesions, compared to 67% and 23% for FIT.6PubMed. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening The improved test still had a higher false positive rate than FIT, which is a real consideration if you are someone prone to anxiety about medical results.
The practical point is this: if you received a positive stool-based screening test, that does not mean you have cancer. It means the test found something worth investigating further, and a colonoscopy will be needed to find out what is going on. Many positive stool tests turn out to be false alarms or lead to the discovery of benign polyps rather than cancer.
What Happens When Polyps Are Found
The most common finding during a screening colonoscopy is one or more polyps, which are small growths on the lining of the colon. Finding polyps during screening is extremely common and, in the vast majority of cases, not a cancer diagnosis. Most polyps are benign. They are removed during the colonoscopy and sent to a lab for analysis, and you get results within a week or two.
The size and type of polyp matter a lot. An analysis of over 750 polyps found during colonoscopy screening showed that none of the small polyps (6 to 9 mm) were cancerous, and only about 4% of them had any kind of advanced features.7Clinical Gastroenterology and Hepatology. Patient-Specific Analysis of Colorectal Polyp Histology and Size from CT Colonography Screening Even among medium-sized polyps (10 to 19 mm), less than 1% were malignant. Cancer was really only found with any frequency in large polyps 30 mm or bigger, where about 38% were malignant. Since most polyps found during screening are small, the odds are strongly in your favor.
After polyps are removed, your follow-up schedule depends on what the lab report shows. For one or two small tubular adenomas under 10 mm with no high-grade features, guidelines recommend a relatively relaxed follow-up: a stool-based screening test in about five years rather than an immediate repeat colonoscopy.8PubMed Central. Post-polypectomy surveillance: follow-up recommendations from the Alberta Colorectal Cancer Screening Program Research supports this approach because people who have small, low-risk adenomas removed have a cancer risk similar to people whose colonoscopy was completely normal, and a lower risk than people who have never been screened at all. If your polyps were larger, more numerous, or showed high-grade features, your doctor will likely recommend a closer surveillance interval, potentially a repeat colonoscopy in one to three years.9PubMed Central. Optimal Colonoscopy Surveillance Interval after Polypectomy
Why Screening Works So Well for Colon Cancer
Colon cancer is one of the cancers where screening has the biggest impact, and the reason is biological. Most colorectal cancers develop through a slow, step-by-step process in which a normal cell in the colon lining accumulates genetic changes over many years, first becoming a small polyp, then a larger and more abnormal polyp, and eventually, in some cases, a cancer.10PubMed Central. Pathways of Colorectal Carcinogenesis This progression, sometimes called the adenoma-carcinoma sequence, involves specific mutations that accumulate in a particular order, each one pushing the cell further toward uncontrolled growth.11PubMed Central. Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity
The crucial point is that this process is slow. Estimates based on modeling suggest that a small polyp can take well over a decade to progress to cancer.12PubMed Central. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy That long window is what makes screening so effective: there is a wide span of time during which a polyp can be found and removed before it ever becomes dangerous. When you go in for a screening colonoscopy and the doctor removes a polyp, they are interrupting that process. The polyp is gone. The potential cancer never gets the chance to develop.
Not all colorectal cancers follow this slow pathway. A minority develop more rapidly through different biological routes, which is one reason no screening method catches everything. But the traditional polyp-to-cancer progression is the dominant pattern, and it is the one that screening is designed to intercept.
Understanding Your Portal Results Without Panicking
Patient portals have become the default way that many health systems deliver test results, and they are generally a good thing for patient engagement. But the speed and clinical language of portal results can create unnecessary alarm, especially for people who are already anxious about cancer screening. Research has documented that disparities in who registers for and actively uses patient portals are linked to health literacy, education level, and race, meaning the burden of confusing portal language falls unevenly.13Journal of the American Medical Informatics Association. Disparities in registration and use of an online patient portal among older adults: findings from the LitCog cohort
If you see “encounter for screening for malignant neoplasm of colon” on your portal and feel a jolt of fear, here are a few things to keep in mind. First, the word “screening” is the operative word. It means the visit was preventive. Second, “malignant neoplasm” in this context is the name of the condition being screened for, not a finding. Your record is not saying you have a malignant neoplasm; it is saying the purpose of your visit was to check for one. Third, if cancer were actually found, you would not learn about it from a billing code on a portal. You would be contacted directly by your doctor’s office to discuss results and next steps.
The same logic applies to related codes you might see, such as Z12.12 (“encounter for screening for malignant neoplasm of rectum”) or Z86.010 (“personal history of colonic polyps”). These are administrative labels, not diagnoses. They exist so the healthcare system can categorize your visit and your insurer can process the claim correctly.
When a Screening Does Find Something Concerning
Even though “encounter for screening” does not mean you have cancer, it is worth knowing what happens in the small number of cases where screening does reveal something that needs attention. If a colonoscopy finds a polyp that turns out to have cancerous cells, or if a stool-based test is positive and the follow-up colonoscopy identifies a suspicious mass, your doctor will shift from screening mode to diagnostic mode. The billing codes will change accordingly, and you will be referred for further evaluation, which may include imaging, biopsies, or specialist consultations.
The key thing screening buys you is early detection. Colorectal cancers found through routine screening tend to be caught at earlier stages than those found because of symptoms like bleeding, unexplained weight loss, or changes in bowel habits. Earlier-stage cancers are far more treatable, which is the entire rationale for having a screening program in the first place. The brief discomfort and anxiety of a screening procedure exist in service of catching problems when they are small and manageable.
Cost can be a barrier to follow-up even when screening itself is free. Research modeling the impact of waiving coinsurance for follow-up colonoscopy after a positive stool test in a Medicare population found that removing that financial barrier could prevent additional colorectal cancer cases and deaths over a ten-year period.14AACR Journals. Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population The implication: if you receive a positive stool test and are worried about the cost of a follow-up colonoscopy, it is worth checking with your insurer or asking your doctor’s office about financial assistance programs, because the follow-up is genuinely important.
Common Misconceptions About Colon Cancer Screening Codes
Beyond the “encounter for screening” confusion, a few other misunderstandings regularly come up. One is that a positive stool test means cancer. It does not. A positive FIT or stool DNA test means the test detected something that warrants a closer look. The majority of people who get a positive stool test and go on to have a colonoscopy turn out to have polyps or nothing at all. Actual cancer is found in a relatively small fraction of follow-up colonoscopies.
Another misconception is that polyps are cancer. As covered earlier, most polyps are benign and will never become cancerous, especially when they are small. Finding and removing them is the goal of screening, and having polyps removed is a success of the screening process, not a failure of your body.
A third misconception is that only people with symptoms or family history need to be screened. Current guidelines recommend screening for all adults starting at age 45, regardless of symptoms or family history.3JAMA. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement In fact, the whole point of screening is to find problems in people who feel fine. If you already have symptoms, what you need is a diagnostic workup, not a screening. The “encounter for screening” code exists precisely because you are a healthy person going in for a preventive check.
How Health Literacy Shapes the Experience
The confusion over medical billing codes is not evenly distributed across the population. People with lower health literacy, less formal education, and less experience navigating the healthcare system are more likely to misinterpret what they see in a patient portal and less likely to have someone nearby who can explain it. Studies of patient portal usage among older adults have found stark disparities in who registers for portal access and who actively uses it, with health literacy and education being major predictors.13Journal of the American Medical Informatics Association. Disparities in registration and use of an online patient portal among older adults: findings from the LitCog cohort Those who do use portals but have lower health literacy are more vulnerable to the kind of alarm that a phrase like “malignant neoplasm” can trigger.
Health systems are slowly recognizing this problem. Some have started adding plain-language explanations alongside billing codes and lab results in their portals, though the practice is far from universal. If your portal offers a messaging feature, using it to ask your care team to explain unfamiliar terms is a reasonable step and exactly the kind of follow-up these systems are designed to support. You are not wasting anyone’s time by asking what a code means. Medical professionals know that their jargon is confusing, and most would rather you ask than spend a week worrying that a billing code is a cancer diagnosis.